NDAORALTABLET
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
5/8 — Partial
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAZANO is a fixed-dose oral combination tablet containing alogliptin (a DPP-4 inhibitor) and metformin HCl (a biguanide) for type 2 diabetes mellitus. Alogliptin increases incretin hormone concentrations to promote glucose-dependent insulin release, while metformin decreases hepatic glucose production and improves insulin sensitivity. Together, they lower both fasting and postprandial glucose levels in patients with inadequate glycemic control.
$112KPart D
Peak3.1 years to LOEModest Part D utilization signals a niche product in peak lifecycle with limited team expansion opportunities relative to blockbuster competitors.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
Started Feb 2017
1,026 enrolled
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
Started Jan 2007
480 enrolled
Diabetes Mellitus, Type 2
Why This Matters for Your Career
Worked on KAZANO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.